Search Results - "Božin, Ivan"

Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis by Jiang, Tammy, Ziemssen, Tjalf, Wray, Sibyl, Shen, Changyu, Söderbärg, Karin, Lewin, James B., Božin, Ivan, Freedman, Mark S.

“…Introduction Diroximel fumarate (DRF), ponesimod (PON), and teriflunomide (TERI) are oral disease-modifying therapies approved for the treatment of relapsing…”
Get full text

Diroximel fumarate pregnancy outcomes in EVOLVE-MS-1 and prospective MS pregnancy exposure registry study design by Maria, Houtchens, Annette, Wundes, Benjamin, Osborne, Ivan, Božin, Hailu, Chen, Heather, Davies, Seth, Levin, Xiaochen, Lin, Matthew, Scaramozza, Kerstin, Hellwig

“…ObjectiveReport pregnancy outcomes from diroximel fumarate (DRF)-exposed women with multiple sclerosis (MS) in EVOLVE-MS-1, and describe a prospective,…”
Get full text

Response to Letter to the Editor Regarding “Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis” by Lager, Brittney, Liseno, Jacob, Božin, Ivan, England, Sarah M., Shankar, Sai L., Mendoza, Jason P., Lewin, James B.

Get full text

Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis by Lager, Brittney, Liseno, Jacob, Božin, Ivan, England, Sarah M., Shankar, Sai L., Mendoza, Jason P., Lewin, James B.

“…Introduction Adherence to disease-modifying therapies is key for achieving optimal outcomes in multiple sclerosis (MS). Diroximel fumarate (DRF) is an oral…”
Get full text

Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM by Williams, Mitzi J., Amezcua, Lilyana, Chinea, Angel, Cohan, Stanley, Okai, Annette, Okuda, Darin T., Vargas, Wendy, Belviso, Nick, Božin, Ivan, Jiang, Xiaotong, Lewin, James B., Lyons, Jennifer, Shen, Changyu, England, Sarah M., Grimes, Nydjie

“…Introduction Multiple sclerosis (MS) clinical trials have included low numbers of patients from racial and ethnic minority populations; therefore, it is…”
Get full text

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons by Jiang, Tammy, Shanmugasundaram, Mathura, Božin, Ivan, Freedman, Mark S, Lewin, James B, Shen, Changyu, Ziemssen, Tjalf, Arnold, Douglas L

“…Diroximel fumarate (DRF), ozanimod (OZA) and interferon beta-1a (IFN) are disease-modifying therapies approved for the treatment of relapsing multiple…”
Get full text

Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration by Bozin, Ivan, Ge, Yulin, Kuchling, Joseph, Dusek, Petr, Chawla, Sanjeev, Harms, Lutz, Ruprecht, Klemens, Niendorf, Thoralf, Paul, Friedemann, Kister, Ilya, Sinnecker, Tim, Wuerfel, Jens

“…The analysis of the MR phase provides additional information on the tissue microstructure. In multiple sclerosis (MS) lesions phase alterations may reflect…”
Get full text

Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase by Spelman, Tim, Eichau, Sara, Alroughani, Raed, Ozakbas, Serkan, Khoury, Samia J, Patti, Francesco, Kubala Havrdova, Eva, Boz, Cavit, Terzi, Murat, Kuhle, Jens, Grammond, Pierre, Lechner-Scott, Jeanette, Gray, Orla, Amato, Maria Pia, Laureys, Guy, Shaygannejad, Vahid, Hyde, Robert, Wang, Haijue, Bozin, Ivan, Belviso, Nicholas, Quan, Chao, Zeng, Feng, van der Walt, Anneke, Butzkueven, Helmut

“…Background The use of non-specific immunosuppressants (NSIS) to treat multiple sclerosis (MS) remains prevalent in certain geographies despite safety concerns,…”
Get full text

Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 after Re-baselining in the Phase 3 EVOLVE-MS-1 Study (P8-3.001) by Bowen, James, Stulc, Jessica, Hunter, Samuel, Antezana, Ariel, Chen, Hailu, Lewin, James, Scaramozza, Matthew, Bozin, Ivan, Bergh, Florian Then

“…Abstract only…”
Get full text

Long-Term Safety and Effectiveness of Delayed-release Dimethyl Fumarate in Multiple Sclerosis Patients Treated in Routine Medical Practice, an updated analysis of the ESTEEM Study (P7-3.009) by Pandey, Krupa, Giles, Kathryn, Balashov, Konstantin, Macdonell, Richard, Windsheimer, Jorg, Martinez, Mikel, Bozin, Ivan, Jiang, Xiaotong, Lyons, Jennifer, Mokliatchouk, Oksana, Okai, Annette

“…Abstract only…”
Get full text

Diroximel Fumarate Pregnancy Outcomes in EVOLVE-MS-1 and Study Design of Diroximel Fumarate Prospective MS Pregnancy Exposure Registry (P9-3.003) by Houtchens, Maria, Wundes, Annette, Osborne, Benjamin, Bozin, Ivan, Branco, Filipe, Chen, Hailu, England, Sarah, Gerber, Nancy, Levin, Seth, Lin, Xiaochen, Scaramozza, Matthew, Hellwig, Kerstin

“…Abstract only…”
Get full text

Long-Term Safety and Effectiveness of Delayed-release Dimethyl Fumarate in Multiple Sclerosis Patients Treated in Routine Medical Practice (P7-4.009) by Pandey, Krupa, Giles, Kathryn, Balashov, Konstantin, Macdonell, Richard, Windsheimer, Jorg, Martinez, Mikel, Bozin, Ivan, Grimes, Nydije, Jiang, Xiaotong, Kapadia, Shivani, Lyons, Jennifer, Mokliatchouk, Oksana, Okai, Annette

“…Abstract only…”
Get full text

Diroximel Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study by Bowen, James D., Stulc, Jessica, Hunter, Samuel F., Chen, Hailu, Lewin, James B., Scaramozza, Matthew, Bozin, Ivan, Then Bergh, Florian

“…Introduction Diroximel fumarate (DRF) and dimethyl fumarate (DMF) are orally administered fumarate disease-modifying therapies (DMTs) for multiple sclerosis…”
Get full text

Identical lesion morphology in primary progressive and relapsing–remitting MS –an ultrahigh field MRI study by Kuchling, Joseph, Ramien, Caren, Bozin, Ivan, Dörr, Jan, Harms, Lutz, Rosche, Berit, Niendorf, Thoralf, Paul, Friedemann, Sinnecker, Tim, Wuerfel, Jens

“…Potential differences between primary progressive (PP) and relapsing–remitting (RR) multiple sclerosis (MS) have been controversially discussed. In this study,…”
Get full text

Vaccine response in people with multiple sclerosis treated with fumarates by Tremblay, Matthew A., Vukusic, Sandra, Shanmugasundaram, Mathura, Bozin, Ivan, Levin, Seth, Gocke, Anne, Wipfler, Peter

“…People with multiple sclerosis (pwMS) have an increased risk of infection. As disease-modifying therapies (DMTs) and other treatments may interact with the…”
Get full text

Periventricular venous density in multiple sclerosis is inversely associated with T2 lesion count: a 7 Tesla MRI study by Sinnecker, Tim, Bozin, Ivan, Dörr, Jan, Pfueller, Caspar F, Harms, Lutz, Niendorf, Thoralf, Brandt, Alexander U, Paul, Friedemann, Wuerfel, Jens

“…Background: Damage to venules in multiple sclerosis was first described decades ago. Today, ultrahigh magnetic field strength T2*-weighted magnetic resonance…”
Get full text

Is Primary Progressive Multiple Sclerosis A Disease Entity Of Its Own? - Preliminary Results Of A 7T MRI Study (S54.002) by Kuchling, Joseph, Bozin, Ivan, Dörr, Jan-Markus, Harms, Lutz, Rosche, Berit, Niendorf, Thoralf, Paul, Friedemann, Sinnecker, Tim, Wuerfel, Jens

“…Abstract only…”
Get full text

Different patterns of lesion formation in early and late stages of multiple sclerosis revealed by phase imaging at 7T (P6.115) by Bozin, Ivan, Ge, Yulin, Kuchling, Joseph, Dusek, Petr, Chawla, Sanjeev, Harms, Lutz, Ruprecht, Klemens, Niendorf, Thoralf, Paul, Friedemann, Kister, Ilya, Sinnecker, Tim, Wuerfel, Jens

“…Abstract only…”
Get full text